Citigroup’s Kite Pharma, Inc. KITE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-59,700
Closed -$10.7M 7795
2017
Q3
$10.7M Buy
59,700
+21,600
+57% +$3.01M 0.01% 1192
2017
Q2
$3.95M Buy
38,100
+23,000
+152% +$1.88M ﹤0.01% 1912
2017
Q1
$1.19M Sell
15,100
-7,900
-34% -$488K ﹤0.01% 3033
2016
Q4
$1.03M Sell
23,000
-4,900
-18% -$240K ﹤0.01% 3662
2016
Q3
$1.56M Sell
27,900
-44,600
-62% -$2.48M ﹤0.01% 2754
2016
Q2
$3.63M Buy
72,500
+48,600
+203% +$2.39M ﹤0.01% 1863
2016
Q1
$1.1M Sell
23,900
-500
-2% -$24.2K ﹤0.01% 3229
2015
Q4
$1.5M Sell
24,400
-16,400
-40% -$1.15M ﹤0.01% 2717
2015
Q3
$2.27M Buy
40,800
+6,700
+20% +$421K ﹤0.01% 2334
2015
Q2
$2.08M Buy
34,100
+33,800
+11,267% +$1.93M ﹤0.01% 2480
2015
Q1
$17K Buy
+300
New +$20.1K ﹤0.01% 6193

Citigroup's KITE Position: Q4 2017 in Review

Citigroup sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 356,484 shares — an estimated $64.1M sold.

Citigroup first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $64.1M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Citigroup reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Citigroup sold 356,484 Kite Pharma, Inc. shares in Q4 2017, an estimated $64.1M.
  • Citigroup first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
  • Citigroup's Kite Pharma, Inc. position peaked at $64.1M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Citigroup's 13F filing for Q4 2017, filed 12 Feb 2018.